Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Understanding of Receptor Regulation Suggests Target for New Drugs

By BiotechDaily International staff writers
Posted on 09 Jan 2013
A study leading to improved understanding of G-protein coupled receptor regulation suggests a new set of targets for designing drugs to more effectively regulate this medically important family of receptors.

More than one-third of drugs on the market directly or indirectly regulate G protein-coupled receptors (GPCRs). Some indirect drugs trigger beta arrestins that downregulate activated GPCRs mainly by causing the receptors to be removed from the cell surface to be subsequently recycled or, via ubiquitination, degraded. The natural action of beta arrestins lowers the cell surface concentration of GPCRs and so can interfere with drugs designed to directly target GPCRs, in some cases leading to drug tolerance in patients and a need for using higher doses.

The current study, led by principal investigator Carlos E. Alvarez, PhD, at Nationwide Children's Hospital (Columbus, OH, USA), identified related GPCR regulatory roles by another subfamily of arrestins, the “alpha arrestins,” recently discovered by Dr. Alvarez’s laboratory. Using biochemical and imaging approaches, the researchers now found that alpha arrestins respond to ligand-bound receptor activation, and recruit enzymes that chemically modify the receptor to initiate aspects of down-regulation. Time course studies showed that these effects occur in the first 1-5 minutes after ligand activation, the same time frame that beta arrestins are known to trigger receptor downregulation. Using coimmunoprecipitation and co-localization methods, the researchers were also the first to find strong evidence suggesting that alpha arrestins function coordinately with beta arrestins.

"Our findings suggest that alpha arrestins, like beta arrestins, are ubiquitous regulators of G-protein coupled receptor signaling," said Dr. Alvarez. A major effort in current pharmacology is to develop drugs with functional selectivity that target either G protein or beta arrestin signaling effects. Dr. Alvarez foresees alpha arrestins becoming important in refining such efforts. "Just as has been discovered with beta blockers and beta arrestin, I expect we'll find drugs that also have significant alpha arrestin effects," said Dr. Alvarez.

The study was published online December 7, 2012, in the journal PLoS One.

Related Links:
Nationwide Children's Hospital




Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.